slow responder to semaglutide Everyone wants be a super to the GLP1s, most people are not. Super responders are more sensitive to GLP1 medications often at lower doses and lose more weight than average TrimRX | Not Losing Weight

80.2% at Week 48 (placebo: -5.27%)

A counteracting agent may be the stable gastric pentadecapeptide BPC 157 (GEPPPGKPADDAGLV, MW 1419, an anti-ulcer peptide per-orally active (12-15) that may also affect many central disturbances (16-23), efficient in inflammatory bowel disease trials (PL 14736) (24, 25) and various wound treatment (26-28), no toxicity reported (12, 13, 24, 25)) which showed various hepatoprotective effects (29-31)

Patients with IBS-C (constipation-dominant) may experience worsening symptoms within weeks of starting therapy, while those with IBS-D (diarrhea-dominant) sometimes report improvement in urgency and stool frequency

A comprehensive review of the strategies to reduce retinoid-induced skin irritation in topical formulation

Yes, its scientifically plausible